Clinical Trial

Firstline Sequential AG and mFOLFOX Combined With Serplulimab and Bevacizumab Versus AG Chemotherapy Alone in Advanced Pancreatic Cancer

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
A randomized, multicenter, Phase III trial evaluating the efficacy and safety of first-line Sequential AG-mFOLFOX chemotherapy combined with Serplulimab and Bevacizumab versus AG chemotherapy alone in advanced pancreatic cancer. The primary endpoint is Overall Survival (OS). Approximately 292 patients will be enrolled in China.
Trial Details
NCT Number NCT07235930
Lead Sponsor Zhejiang Cancer Hospital
Conditions Non-Resectable Pancreas Carcinoma
Enrollment 292 participants
Start Date 2025-11-15
Primary Completion 2029-07-01 (estimated)
Study Completion 2029-07-01 (estimated)
Updated on ClinicalTrials.gov 2025-11-19